Monash University researchers, alongside key partner Halozyme Therapeutics, report findings in support of shifting the way ...
Subcutaneous immunotherapy injections work the same way as their intravenous counterparts — by changing or enhancing a person’s immune responses to cancer. Immunotherapy for cancer is a broad category ...
The U.S. Food and Drug Administration has approved Leqembi Iqlik, a subcutaneous version of lecanemab, for weekly maintenance after the 18-month intravenous (IV) phase. Leqembi Iqlik is a subcutaneous ...
SAN DIEGO, Feb. 3, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (HALO) (Halozyme) today announced that Janssen-Cilag International NV, a Johnson & Johnson company, received a positive opinion from ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved atezolizumab and hyaluronidase-tqjs for subcutaneous injection. The agent (Tecentriq Hybreza, ...
This newer mode of administration for immunotherapy comes with benefits and risks. It is important for a person to work with a doctor when making treatment decisions for upper gastrointestinal (GI) ...
SAN DIEGO, CA—Use of a subcutaneous implantable cardioverter-defibrillator (S-ICD) appears to have some advantages over transvenous devices for patients with an ICD indication but no need for pacing, ...
Horizon Therapeutics has teamed up with Xeris Biopharma to create an ultra-concentrated, ready-to-use, subcutaneous formulation of teprotumumab, handing over an upfront payment and offering milestones ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results